Innovative tools for the diagnosis and treatment of neurological diseases


We are devoted to the challenging task of developing innovative solutions for an enhanced clinical management of patients who suffer from highly prevalent neurological diseases such as stroke and Alzheimer’s disease.

Research Areas


Our first product Minerva, consists of a clinical decision support system (CDSS) that provides useful insights to clinicians for an enhanced clinical management of stroke patients.

Alzheimer’s Disease and other Tauopathies

We are developing the next generation of monoclonal antibodies (with high affinity to several Tau aberrant species) with multiple applications in the diagnosis and treatment of AD. Our first product in this field is a novel ELISA kit to detect misfolded proteins in Cerebrospinal fluid (CSF), thus allowing diagnosis of the disease even at its subclinical stage. Early diagnosis of AD is essential to improve patients’ prognosis.


Stroke market

  • Total costs for stroke were estimated at €64 billion across Europe in 2010.
  • Around 1 in 6 men will have a stroke in their life.
  • Around 1 in 5 women will have a stroke in their life.
  • The rate of first-time strokes in people aged 45 and over.
  • Expected to increase by 59% in the next 20 years (between now and 2035).

Alzheimer’s disease market

  • Alzheimer’s disease (AD) is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks.
  • According to Alzheimer’s Disease International, today, over 46 million people live with dementia worldwide, more than the population of Spain. This number is estimated to increase to 131.5 million by 2050.
  • The average annual cost for Alzheimer’s disease in Europe was €250bn in 2017 (one year), with a substantial economic impact, equivalent to almost 1,5% of the EU-27’s GDP.


Parque Tecnológico de Galicia
Ed. Tecnópole 1, 32900
San Cibrao das Viñas, Ourense


+34 988 980 631